“Syringe plunger contamination by hazardous drugs: A comparative study” Barbara Ann Karmanos Cancer Center, Detroit, MI, Stephen T Smith and Mark C Szlaczky
“Application of vapor containment protocol for CSTD to assess efficacy
during pharmacy compounding and administration of HD” Eshelman School of Pharmacy, University of North Carolina
Charlotte M. Forshay, Shawn O. Streeter, Stephanie A. Salch, Stephen F. Eckel
CLINICALLY PROVEN, ELIMINATES SURFACE CONTAMINATION
“Use of Equashield CSTD eliminates surface contamination with antineoplastic agents” Cleveland Clinic Cancer Center, OH Bernadette A Clark and Paul JM Sessink
CUT THE TIME TO COMPOUND IN HALF, TIME SAVED IS MONEY EARNED
“Assessing the efficiency of CSTDs for compounding”
Fouzia Berdi, Pharm.D., Michael F Powell, MS. FASHP et al.
PREVENTS MICROBIAL INGRESS UP TO 7 DAYS*
“A 7 Days Microbial Ingress Test of Single Use Vials Utilizing the EQUASHIELD CSTD” Study by Nelson Laboratories, Salt Lake City, UT
“Evaluation Of A New Closed System Transfer Device” Odette Cancer Centre, Sunnybrook Health Sciences Centre, TORONTO, CANADA H. Scott, S. Singh et al.
“Contamination of syringe plungers during the sampling of cyclophosphamide solutions” Le´on Be´rard Cancer Center, Lyon, France Bertrand Favier, Laurence Gilles et al.
6 CSTDs tested based on NIOSH’s suggested draft protocol: “A Vapor Containment Performance Protocol for CSTDs Used During Pharmacy Compounding and Administration of Hazardous Drugs”
*Study not funded by NIOSH
“Equashield is cleared by the FDA under the ONB code for Closed Antineoplastic and hazardous reconstitution and transfer systems”
“Treatment time, ease of use and cost associated with use of Equashield, PhaSeal, or no cSTD for administration of cancer chemotherapy to a dog model” MULTYSITE STUDY: College of Veterinary Medicine University of Georgia and 11 CLINICS AND HOSPITALS K. Kicenuik, N. Northrup et al.
“Evaluation of syringes used for compounding hazardous drugs and the contamination risks to healthcare personnel”
Study Presented at the ASHP Midyear 2014 Residents Poster Session
“Treanda Bendamustine, ETOPOSIDE, BUSULFAN and PACLITAXEL Antineoplastic Drugs Compatibility with the EQUASHIELD CSTD” Milouda & Migal Laboratories, K.SHMONA, ISRAEL Dr. Igal Bar-Ilan
“Evaluation of Equashield CSTD Compatibility in Prevention of Environmental Contamination, Alcohol vapors detection” Milouda & Migal Laboratories, K.SHMONA, ISRAEL
“A Vapor Containment Performance Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs” THE NIOSH DRAFT PROTOCOL